iTeos Therapeutics Inc. (ITOS): Price and Financial Metrics Recent IPO


iTeos Therapeutics Inc. (ITOS) Recent IPO

Today's Latest Price: $26.54 USD

0.42 (1.61%)

Updated Nov 24 4:00pm

Add ITOS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ITOS Stock Price Chart Interactive Chart >

Price chart for ITOS

ITOS Price/Volume Stats

Current price $26.54 52-week high $34.33
Prev. close $26.12 52-week low $17.50
Day low $25.33 Volume 75,100
Day high $26.78 Avg. volume 174,762
50-day MA $24.15 Dividend yield N/A
200-day MA $0.00 Market Cap 930.09M

iTeos Therapeutics Inc. (ITOS) Company Bio


iTeos Therapeutics, Inc. engages in the development of biopharmaceuticals therapeutic products and services. It offers immuno-oncology therapeutics for patients. The company was founded by Michel Detheux in April 2012 and is headquartered in Cambridge, MA.


ITOS Latest News Stream


Event/Time News Detail
Loading, please wait...

ITOS Latest Social Stream


Loading social stream, please wait...

View Full ITOS Social Stream

Latest ITOS News From Around the Web

Below are the latest news stories about iTeos Therapeutics Inc that investors may wish to consider to help them evaluate ITOS as an investment opportunity.

ITeos Therapeutics prices IPO at $19

Oncology biotech, iTeos Therapeutics (ITOS) has priced its IPO of 10,586,316 shares of common stock at $19.00/share (above range of $16-18), for expected gross proceeds of ~$201.1M.Underwriters' over-allotment is an additional 1,587,947 shares.Trading kicks off today. Closing date is July 28....

Seeking Alpha | July 24, 2020

U.S. debut on horizon for iTeos Therapeutics

ITeos Therapeutics (ITOS) has filed a preliminary prospectus for a $100M IPO.The Cambridge, MA-based biopharmaceutical firm leverages its know-how in small molecule and monoclonal antibody development to discover novel cancer candidates that target immunometabolism and immunosuppression in the tumor microenvironment.Lead small molecule candidate is EOS-850, an antagonist of the adenosine...

Seeking Alpha | June 25, 2020

Read More 'ITOS' Stories Here

ITOS Price Returns

1-mo 12.98%
3-mo -2.50%
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8383 seconds.